Happy Holidays from the MS Society research team!
As the end of 2015 draws near, I can’t help but feel a sense of hope and pride as I reflect upon what…
Vitamin D and MS: What we’ve learned over the past year
It’s been over a year since my last major update on vitamin D in which I summarized highlights from the Vitamin D Consensus…
Microglia: Friend or foe?
People living with multiple sclerosis know all too well that for them, the immune system is a double-edged sword. Although it acts as…
On GivingTuesday we rally for an important cause
The ability for the MS Society to fund groundbreaking, meaningful research that propels treatment development and improves health would not be possible without…
Research Decoder: Gut Microbiome
Our digestive tract contains trillions of bacteria encompassing thousands of different species that collectively make up the gut microbiome. In fact, the number…
ECTRIMS 2015 Highlights and General Impressions, Part III
Continuing on our recap of ECTRIMS 2015, the topics that arguably made the biggest splash at this year’s meeting concerned new and repurposed…
ECTRIMS 2015 Highlights and General Impressions, Part II
Welcome back to my ECTRIMS 2015 recap. In the previous post I covered some of the crucial research being undertaken to further understand…
ECTRIMS 2015 Highlights and General Impressions, Part I
Now that the dust from this year’s ECTRIMS meeting has finally settled, I’ve had the chance to sit back and reflect on my…
Ocrelizumab marks an important milestone in research and treatment for progressive MS
Over 20 years ago, the first disease modifying therapy was approved in Canada for relapsing remitting MS, and since then we have seen…
Encouraging results presented at ECTRIMS Late Breaking News session
Perhaps the most anticipated session at ECTRIMS is “Late Breaking News”, which features a selection of exciting and newly released clinical trial results…